Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $210 and keeps an In Line rating on the shares after the company reported a “solid” Q1 beat and raised FY26 guidance. The firm sees updated guidance as “achievable with potential upside,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $225 from $220 at Jefferies
- Midday Fly By: Apple names new CEO, Amazon ups investment in Anthropic
- Early notable gainers among liquid option names on April 21st
- Quest Diagnostics: Sustained Volume Growth and Upgraded Revenue Outlook Justify Premium Valuation and Buy Rating
- Quest Diagnostices reports Q1 adjusted EPS $2.50, consensus $2.37